



## **GIACONDA SIGNS NON- BINDING LETTER OF INTENT FOR MYOCONDA® COMMERCIALISATION IN BENELUX TERRITORY**

**Sydney, Australia, 22 September 2006: Giaconda (ASX: GIA)** today announced that the Company has signed a non-binding letter of intent (LOI) with Tramedico International BV (Netherlands) regarding the licensing and commercialisation of its lead product for Crohn's disease, Myoconda® in the Benelux countries.

In this LOI Tramedico has expressed its intention to undertake due diligence with the objective of acquiring the exclusive rights to commercialise Myoconda® in Netherlands, Belgium and Luxembourg. Licensing agreement discussions will commence subsequent to the due diligence process and prior to the commencement of the next clinical trial on Myoconda®.

"We are pleased with the progress we are making in securing interest in our lead product for the European market," said Patrick McLean, CEO of Giaconda. "This is the second LOI we have signed in Europe and we are confident in Tramedico's ability to successfully market Myoconda® in the Benelux region. The Tramedico sales force already markets a number of GI products to gastroenterologists in the region and has an excellent understanding of their needs as well as Crohn's Disease itself," he added.

"Crohn's disease affects over 24,500 people in the Benelux region and the commercialisation of Myoconda® will give us an opportunity to provide alternative treatment to those patients who fail currently available treatments," commented Mr. HJ de Graaf, Managing Director of Tramedico International B.V.

### **About Giaconda Limited**

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda® for the treatment of Crohn's Disease and Heliconda® for the treatment of resistant *Helicobacter pylori* infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa already complete for Myoconda®.

For more information please visit [www.giacondalimited.com](http://www.giacondalimited.com)

*Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*

GIACONDA LIMITED

Suite 1307, Level 13, 370 Pitt Street, Sydney NSW 2000 Phone: [612] 9266 0440 Fax: [612] 9266 0441

email: [info@giaconda.net.au](mailto:info@giaconda.net.au) ABN 68 108 088 517 [www.giaconda.net.au](http://www.giaconda.net.au)



### About Tramedico International BV

Tramedico is an independent family-owned pharmaceutical company that markets, sells and distributes medicines and consumer healthcare products in the Benelux (the Netherlands, Belgium and Luxembourg). Tramedico represents also several foreign companies, including Dr Mann Pharma, Dr Falk Pharma and Tedec Meiji. Tramedico offers a complete range of services including regulatory, medical and marketing and sales services. For several companies Tramedico also provides a complete package of pre-wholesaling services throughout the Benelux countries, including MEDA AB, ZLB Behring and IPSEN.

Over the past 33 years Tramedico has secured a strong market position in the therapeutic areas of ophthalmology, rheumatology, dermatology and gastroenterology. With product ranges in food supplements, phyto pharmaceuticals and skin care, Tramedico is also active in various OTC markets in the Benelux.

For more information please visit [www.tramedico.com](http://www.tramedico.com)

### CONTACTS:

<b>Giaconda</b>	<b>Media &amp; Investor Relations</b>
Patrick McLean – Chief Executive Officer	Fay Weston – Talk Biotech
T: +1 51 4815 2501	T: +61 422 206036
E: pmclean@giacondalimited.com	E: fayweston@talkbiotech.com.au

<b>Tramedico International BV</b>	<b>Media &amp; Investor Relations</b>
H.J. de Graaf – Managing Director	M.C. Beunk – Manager Business Development
T: +31 294 46 11 22	T: +31 294 46 11 22
E: hjdegraaf@tramedico.com	E: c.beunk@tramedico.com